The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Efficacy and Safety of Extended-Release Venlafaxine in the Treatment of Generalized Anxiety Disorder in Children and Adolescents: Two Placebo-Controlled Trials
Abstract
OBJECTIVE: The authors evaluated the efficacy, safety, and tolerability of extended-release venlafaxine in the treatment of pediatric generalized anxiety disorder. METHOD: Two randomized, double-blind, placebo-controlled trials were conducted at 59 sites in 2000 and 2001. Participants 6 to 17 years of age who met DSM-IV criteria for generalized anxiety disorder received a flexible dosage of extended-release venlafaxine (N=157) or placebo (N=163) for 8 weeks. The primary outcome measure was the composite score for nine delineated items from the generalized anxiety disorder section of a modified version of the Schedule for Affective Disorders and Schizophrenia for School-Age Children, and the primary efficacy variable was the baseline-to-endpoint change in this composite score. Secondary outcome measures were overall score on the nine delineated items, Pediatric Anxiety Rating Scale, Hamilton Anxiety Rating Scale, Screen for Child Anxiety Related Emotional Disorders, and the severity of illness and improvement scores from the Clinical Global Impression scale (CGI). RESULTS: The extended-release venlafaxine group showed statistically significant improvements in the primary and secondary outcome measures in study 1 and significant improvements in some secondary outcome measures but not the primary outcome measure in study 2. In a pooled analysis, the extended-release venlafaxine group showed a significantly greater mean decrease in the primary outcome measure compared with the placebo group (-17.4 versus -12.7). The response rate as indicated by a CGI improvement score <3 was significantly greater with extended-release venlafaxine than placebo (69% versus 48%). Common adverse events were asthenia, anorexia, pain, and somnolence. Statistically significant changes in height, weight, blood pressure, pulse, and cholesterol levels were observed in the extended-release venlafaxine group. CONCLUSIONS: Extended-release venlafaxine may be an effective, well-tolerated short-term treatment for pediatric generalized anxiety disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
SHAFFER, D., FISHER, P., LUCAS, C. P., DULCAN, M. K., & SCHWAB-STONE, M. E. (2000) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200001000-00014 · Cited by 3,505
BIRMAHER, B., KHETARPAL, S., BRENT, D., CULLY, M., BALACH, L., KAUFMAN, J., & NEER, S. M. (1997) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199704000-00018 · Cited by 2,846
BIRMAHER, B., BRENT, D. A., CHIAPPETTA, L., BRIDGE, J., MONGA, S., & BAUGHER, M. (1999) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199910000-00011 · Cited by 2,252
ECDEU Assessment Manual: (591322011-001)
Guy, W. (1976) · PsycEXTRA Dataset · doi:10.1037/e591322011-001 · Cited by 1,896
Fluvoxamine for the Treatment of Anxiety Disorders in Children and Adolescents
Walkup, J. T., Labellarte, M. J., Riddle, M. A., Pine, D. S., Greenhill, L., Klein, R., Davies, M., Sweeney, M., Abikoff, H., Hack, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104263441703 · Cited by 588
Self-citationThe Pediatric Anxiety Rating Scale (PARS): development and psychometric properties
P, T. R. U. O. P. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200209000-00006 · Cited by 532
Allgulander, C., Hackett, D., & Salinas, E. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.179.1.15 · Cited by 175
Research works printed but not linked: 29
- 10.1016/S0006-3223(99)00248-6 · DOI
- 10.1097/00008480-199708000-00006 · DOI
- Costello EJ, 1995, Anxiety Disorders in Children and Adolescents, 109
- 10.1111/j.1600-0447.1990.tb05492.x · DOI · Paper page
- 10.1097/00004583-199905000-00017 · DOI · Paper page
- 10.1097/00004583-199907000-00008 · DOI · Paper page
- 10.1001/archpedi.157.1.17 · DOI · Paper page
- 10.1176/appi.ajp.160.4.749 · DOI · Paper page
- 10.1176/appi.ajp.161.9.1642 · DOI
- 10.1002/da.10146 · DOI · Paper page
- Bernstein GA, 2004, Child and Adolescent, 557
- 10.1089/cap.1997.7.17 · DOI
- 10.1097/00004583-199409000-00009 · DOI
- 10.1176/appi.ajp.158.12.2008 · DOI · Paper page
- 10.1097/01.CHI.0000037049.04952.9F · DOI · Paper page
- 10.1176/appi.ajp.157.6.968 · DOI · Paper page
- 10.1001/jama.283.23.3082 · DOI · Paper page
- Chaput F, 1999, Shaffer D: The Columbia KSADS (Schedule for Affective DIsorders and Schizophrenia for School Aged Children)
- Puig-Antich J, 1978, Chambers WJ: Schedule for Affective Disorders and Schizophrenia for School-Age Children (KIDDIE-SADS)
- Poznanski EO, 1985, Psychopharmacol Bull, 21, 979
- 10.1097/00004583-199707000-00021 · DOI · Paper page
- 10.1186/1471-244X-4-26 · DOI
- 10.1001/archpsyc.56.6.493 · DOI · Paper page
- 10.1111/j.1469-7610.1995.tb01300.x · DOI · Paper page
- Davidson JR, 2001, J Clin Psychiatry, 62, 46, 10.4088/JCP.v62n0110 · DOI
- 10.1097/01.chi.0000121065.29744.d3 · DOI · Paper page
- Grunbaum JA, 2004, MMWR Surveill Summ, 53, 1
- Kusiak V, 2003, Penn, Wyeth Pharmaceuticals
- Hammad TA, 2004, Review and Evaluation of Clinical Data
Cited by
Bridge, J. A., Iyengar, S., Salary, C. B., Barbe, R. P., Birmaher, B., Pincus, H. A., Ren, L., & Brent, D. A. (2007) · JAMA · doi:10.1001/jama.297.15.1683 · Cited by 1,086
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Locher, C., Koechlin, H., Zion, S. R., Werner, C., Pine, D. S., Kirsch, I., Kessler, R. C., & Kossowsky, J. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.2432 · Cited by 360
“Heterogeneitywasassessedbycalculating theQ statistic,(27) the τ(2), and the I(2), a transformation ofQ that indicates the proportion of observed variance that can be attributed to heterogeneity rather than sampling error.(28) The τ(2) offers an estimate of the variance among trueeffect sizes.”
Solmi, M., Fornaro, M., Ostinelli, E. G., Zangani, C., Croatto, G., Monaco, F., Krinitski, D., Fusar‐Poli, P., & Correll, C. U. (2020) · World Psychiatry · doi:10.1002/wps.20765 · Cited by 324
Assessment and Treatment of Anxiety Disorders in Children and Adolescents
Wehry, A. M., Beesdo-Baum, K., Hennelly, M. M., Connolly, S. D., & Strawn, J. R. (2015) · Current Psychiatry Reports · doi:10.1007/s11920-015-0591-z · Cited by 294
Metadata
- Authors
- Rynn, M. A., Riddle, M. A., Yeung, P. P., & Kunz, N. R.
- Venue
- American Journal of Psychiatry
- Published
- 2007-02
- Volume
- 164
- Issue
- 2
- Pages
- 290-300
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2115556211
- Cited by
- 188
- References
- 8
- FWCI
- 17.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Safety of Extended-Release Venlafaxine in the Treatment of Generalized Anxiety Disorder in Children and Adolescents: Two Placebo-Controlled Trials. https://app.cochat.ai/papers/10.1176/ajp.2007.164.2.290
- The paper
- Rynn, M. A., Riddle, M. A., Yeung, P. P., & Kunz, N. R. (2007). Efficacy and Safety of Extended-Release Venlafaxine in the Treatment of Generalized Anxiety Disorder in Children and Adolescents: Two Placebo-Controlled Trials. American Journal of Psychiatry. https://doi.org/10.1176/ajp.2007.164.2.290
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.